SCHEMBL2866677

SCHEMBL2866677

Cc1cc(Oc2ccccc2)c(O)cc1-n1nc2c(c1N)c(=O)[nH]c1cc(OC(C)C(=O)O)ccc12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.34
APOBEC3A P31941 1/20 0.34
CTDSP1 Q9GZU7 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
BTK Q06187 6/20 0.33
NTRK1 P04629 1/20 0.33
IGF1R P08069 1/20 0.33
FGFR1 P11362 1/20 0.33
NTRK2 Q16620 1/20 0.33
TDP1 Q9NUW8 1/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
KDM4E B2RXH2 1/20 0.32
TDP2 O95551 1/20 0.32
CYP1A2 P05177 2/20 0.31
CYP2C9 P11712 2/20 0.31
APEX1 P27695 1/20 0.31
CYP3A4 P08684 1/20 0.31
TSHR P16473 1/20 0.31
BLM P54132 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2857657 0.92 POLB (0.37) POLBAPOBEC3ACTDSP1APOBEC3GBTK
SCHEMBL2857869 0.90 SMN1; SMN2 (0.35) POLBBTKNTRK1IGF1RFGFR1
SCHEMBL2867785 0.88 NTRK1 (0.36) POLBBTKNTRK1IGF1RFGFR1
SCHEMBL2867281 0.88 GAA (0.37) POLBBTKNTRK1IGF1RFGFR1
SCHEMBL2861352 0.87 FGFR1 (0.37) BTKNTRK1IGF1RFGFR1NTRK2
SCHEMBL2871146 0.86 MAOA (0.36) POLBBTKNTRK1IGF1RFGFR1
SCHEMBL13025396 0.85 SMN1; SMN2 (0.40) POLBBTKALDH1A1KDM4ETSHR
SCHEMBL2861219 0.80 KYAT3 (0.36) POLBBTKNTRK1IGF1RFGFR1
SCHEMBL2872733 0.79 BTK (0.36) BTK
SCHEMBL5790922 0.79 GAA (0.37) POLBBTKFGFR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7842701-B2 Pyrazoloquinolone derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-11-30 US disclosed
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof TAKEDA PHARMACEUTICAL COMPANY (JP) 2007-12-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281963-A1 Pyrazoloquinolone Derivative And Use Thereof MAP3K20, MAP4K5, MAP4K3 POLB 4153/4885APOBEC3A 4781/4885CTDSP1 3313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.